Recursion Pharmaceuticals, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Salt Lake City, UT
RXRX chart
What traders are saying about $RXRX
Latest postsRecursion Pharmaceuticals, Inc. news
- Iambic Therapeutics wins Bank of America backing with 194% upside forecast
proactiveinvestors.com ·
- Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history
Yahoo Finance Singapore ·
- AI in Predictive Toxicology - Global Strategic Business Report 2026: Capture a $3.2 Billion Market by 2032 as BenevolentAI, Insilico Medicine, Recursion Pharmaceuticals and Revvity Disrupt Testing
Yahoo Finance ·
- Recursion Pharmaceuticals (RXRX) After Phase 2 Data What The REC 4881 Narrative Means For Valuation
Simply Wall St ·
- Form 144 RECURSION PHARMACEUTICALS For: 8 November By Investing.com
Investing.com Nigeria ·
- Recursion Pharmaceuticals, Inc. (RXRX) Options Chain - Yahoo Finance
Yahoo! Finance Canada ·
- Recursion Stock Gets A Lift From Trial Progress And New Board Chair
Simply Wall St ·
- More than 40 Altitude Lab companies have raised $205 million combined. Its program is set to move in 2027.
Stock Titan ·
- News Flash: Analysts Just Made A Meaningful Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts
Moomoo ·
- Is Recursion Pharmaceuticals (RXRX) A Bargain After Q3 Earnings And Clinical Updates?
Yahoo Finance ·
- Recursion Pharmaceuticals director Blake Borgeson sells $155,200 in stock By Investing.com
Investing.com Australia ·
- Form 4 Recursion Pharmaceuticals Inc: Blake Borgeson (Director) For: 3 November
Investing.com Canada ·
Recursion Pharmaceuticals, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M |
| Net income | -$644.8M | -$463.7M | -$328.1M | -$239.5M |
| Diluted EPS | $-1.44 | $-1.69 | $-1.58 | $-1.36 |
| Total assets (year end) | $1.47B | $1.45B | $653.7M | $701.3M |
| Cash and equivalents (year end) | $743.3M | $594.4M | $391.6M | $549.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Recursion Pharmaceuticals, Inc.
- Ticker
- RXRX (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Salt Lake City, UT
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1601830
- Former names
- Recursion Pharmaceuticals, LLC
Frequently asked questions
What exchange is Recursion Pharmaceuticals, Inc. listed on?
Recursion Pharmaceuticals, Inc. trades on the Nasdaq under the ticker symbol RXRX.
What industry is Recursion Pharmaceuticals, Inc. in?
Recursion Pharmaceuticals, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Recursion Pharmaceuticals, Inc. headquartered?
Recursion Pharmaceuticals, Inc.'s business address on file with the SEC is in Salt Lake City, UT.
When does Recursion Pharmaceuticals, Inc.'s fiscal year end?
Recursion Pharmaceuticals, Inc.'s fiscal year ends on December 31.
How much revenue did Recursion Pharmaceuticals, Inc. report?
Recursion Pharmaceuticals, Inc. reported $74.7M in revenue for calendar year 2025, according to its SEC filings.